Application of the H2FPEF Score to a Global Clinical Trial of Patients with Heart Failure with Preserved Ejection Fraction: The TOPCAT Trial

Diagnostic uncertainties and lack of standardized strategies to enrich baseline risk have posed significant challenges to the effective conduct of global trials of heart failure with preserved ejection fraction (HFpEF). Differences in event rates across regions in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT, NCT00094302) underscore the importance of consistent standards for HFpEF diagnosis.1 The recent H2FPEF-score, which uses six routinely available clinical and echocardiographic variables, is the first validated diagnostic algorithm for identification of HFpEF in patients with unexplained dyspnoea2 and offers promise as a screening measure in clinical trials. The TOPCAT trial presents a unique opportunity to evaluate the application of this score in a trial population with known background heterogeneity, and to understand its relationship with risk of clinical events. TOPCAT was a global, phase 3, double-blind, placebo-controlled randomized clinical trial of spironolactone in HFpEF enrolling patients from the Americas (United States, Canada, Brazil, Argentina), Russia, and the Republic of Georgia.3 Eligible patients were those ≥ 50 years with symptomatic HF and left ventricular ejection fraction (EF) ≥ 45%, well-controlled blood pressure, and a serum potassium 30 kg/m2 (2 points), 344 (95%) used ≥ 2 antihypertensive drugs (1 point), 177 (49%) had a history of atrial fibrillation (paroxysmal or persistent, 3 points), 171 (47%) had PASP > 35 mmHg (1 point), 315 (87%) were older than 60 years (1 point), and 307 (85%) had E/e' > 9 (1 point). Overall, 74% and 59% of patients had H2FPEF scores ≥ 5 (corresponding to HFpEF diagnostic probabilities of > 80%) in the Americas and Russia/Georgia, respectively (P = 0.026). Patients with higher scores were more likely to be men, enrolled in the Americas region, carry a history of diabetes mellitus, have lower estimated glomerular filtration rate and greater left atrial and left ventricular volumes, in addition to parameters included in the H2FPEF score (all P < 0.01) (Table 1). There was a trend for greater concentrations of NPs with higher H2FPEF score, although this did not reach statistical significance (P = 0.07) (Figure 1B). Over a 2.7-year mean follow-up, 112 primary outcome events occurred. Higher H2FPEF scores (per point) were associated with increased risk of the primary outcome hazard ratio (HR) 1.12, 95% confidence interval (CI) 1.02–1.23; P = 0.02 (Figure 1C). Similar, yet not statistically significant, associations between the H2FPEF score and the primary endpoint were found in analysis restricted to patients with left ventricular EF ≥ 50% (n = 319) (HR 1.09, 95% CI 0.98–1.21; P = 0.12). The incidence rate of the primary outcome in patients with H2FPEF score ≤ 4, 5–6, and ≥ 7 was 8.3 (95% CI 5.6–12.4), 11.8 (95% CI 8.7–16.0), and 13.7 (95% CI 10.2–18.3), respectively. The association between the H2FPEF score and the primary endpoint did not differ by enrolment strata (recent HF hospitalization or elevated NP) (Pinteraction = 0.57). Higher H2FPEF scores (per point) were also associated with increased risk of HF hospitalization (HR 1.14, 95% CI 1.01–1.27; P = 0.03) and cardiovascular death (HR 1.15, 95% CI 0.98–1.34; P = 0.10) separately, although the latter association did not reach statistical significance. HFpEF is a syndrome that is challenging to differentiate from non-cardiac sources of dyspnoea based on clinical examination alone. Although invasive and/or exercise haemodynamic assessments are available to affirm the HFpEF diagnosis, cost, complexity, procedural risk, and limited availability preclude their use in large clinical trials. In addition, risk enrichment strategies applied in HFpEF trials are subject to important limitations. Thresholds for hospitalization for HF may vary globally and across health systems.5 NP concentrations have traditionally been used to identify HFpEF patients with greater certainty and to enrich risk, however these vary substantially and may be systematically lower in select populations (including black and obese patients).6 In this study, we demonstrate that the H2FPEF score correlates with increased risk of adverse cardiovascular events in the TOPCAT trial. Despite variation in analytic approaches, another group recently independently supported the prognostic value of the H2FPEF score in TOPCAT.7 We further demonstrate that the H2FPEF score was only partially and non-significantly associated with NPs, suggesting that these two parameters may provide orthogonal and incremental information. Among patients determined eligible for enrolment in a large HFpEF trial, we observed that 25% of patients in TOPCAT Americas had diagnostic probabilities of HFpEF < 55% as estimated by the H2FPEF score, while 41% of patients enrolled in TOPCAT Russia/Georgia fell into this lower diagnostic probability. These findings are in keeping with regional differences in event rates suggesting a four-fold lower risk of the primary outcome in Russia/Georgia as compared with the Americas.1 When applied to a referral cohort from Alberta, Canada, the discriminatory value of the H2FPEF score was lower than that observed in the original derivation and internal validation cohorts.8 Taken together, these data emphasize the ongoing need to understand the variability in distribution and performance of the H2FPEF score across global, heterogeneous populations. The study is subject to certain limitations, including the restricted number of patients with available data for H2FPEF score calculation, which may introduce selection bias. The H2FPEF score was derived from a population of patients with unexplained dyspnoea, while we applied it retrospectively to patients deemed to have symptomatic HFpEF by a site investigator in a randomized clinical trial. TOPCAT enrolled patients with left ventricular EF ≥ 45%, which is below accepted diagnostic cut-offs for HFpEF; sensitivity analysis restricted to patients with left ventricular EF ≥ 50% yields directionally consistent, but non-significant findings. Finally, it is uncertain whether its prognostic value can be attributed to the composite score or to individual component elements. Disease heterogeneity and diagnostic uncertainty have long been concerns in explaining the failures of previous HFpEF trials. This simple score based on six routinely collected clinical and echocardiographic variables represents an attractive option as a risk enrichment strategy in enrolment for future global clinical trials of HFpEF. However, future prospective studies are needed to externally validate this diagnostic algorithm in larger samples, determine the scope of its applicability in a broad range of patients with dyspnoea syndromes, and test its utility as a metric of clinical trial eligibility and risk enrichment in HFpEF against current strategies (prior hospitalization for HF and NPs). We would like to acknowledge the contributions of the TOPCAT participants, site investigators, and leadership, including the clinical events committee (Brigham and Women's Hospital, Boston, MA, USA). TOPCAT was supported by the NHLBI (HHSN268200425207C). Conflict of interest: P.L.M. has received consulting fees from Novartis and is supported by a postdoctoral research grant from the South-Eastern Norway Regional Health Authority, the Norwegian Medical Association and the Unger Vetlesen Medical Fund. M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), and serves on advisory boards for Amgen, AstraZeneca, Bayer AG, and Baxter Healthcare. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; and has served on the Advisory Board/Steering Committee/Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ironwood, Merck, Novartis, Sanofi, and United Therapeutics. A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224. E.F.L. has received research grants from NHLBI, Novartis, and Sanofi; and consults for Novartis. B.P. reports receiving consulting fees from Amorcyte, AstraZeneca, Aurasense, Bayer, BG Medicine, Gambro, Johnson receiving research grant support from Forest Laboratories; and holding stock in Aurasense, Relypsa, BG Medicine, and Aurasense. He also reports a pending patent related to site specific delivery of eplerenone to the myocardium. S.D.S. has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Celladon, Gilead, GSK, Ionis Pharmaceutics, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Novartis, Sanofi Pasteur, Theracos, and has consulted for Alnylam, Amgen, AstraZeneca, Bayer, BMS, Corvia, Gilead, GSK, Ironwood, Merck, Novartis, Pfizer, Takeda, and Theracos. All other authors report no other relationships relevant to the contents of this paper to disclose.